

CHECKLIST OF RESPONSIBILITIES FOR SCIENTIFIC EDITORS

Manuscript page number (Without Figures): 25 Rate: 6.2 CNY per page

Editing Fee: <u>155 CNY</u>

Figure count: _____Figure handling time: 105 min Rate: 1 CNY per min

Editing Fee: 105 CNY

XML and PDF converting time: 42 min Rate: 1 CNY per min

Editing Fee: <u>42 CNY</u>

Manuscript word count: 6261

Total Editing Fee: <u>302CNY</u>

Scientific Editor: Jia-Ru Fan

Date of signature: <u>May/12/2022</u> (month/day/year)

		Commen
Item No.	Specific items for verification	ts
Item No.		Yes=[Y]
		No= [N]
	General Information of the Manuscript	
	Name of journal: World Journal of Hepatology	
1	Manuscript NO.: 74948	
	Column: Retrospective Study	
	Title: Direct-acting antivirals for HCV-infected patients with	D.d
	hepatocellular carcinoma	[Y]
	Authors: Kazuto Tajiri, Hiroyuki Ito, Kengo Kawai, Yoshiro Kashii,	
	Yuka Hayashi, Aiko Murayama, Masami Minemura, Terumi Takahara,	
	Yukihiro Shimizu and Ichiro Yasuda	
	Reviewer code: 05395857, and 05261046	



	First decision: 2022-03-16 03:17	
	Editorial Office's Comments	
	Science Editor:1. Please sign the online copyright agreement 【Hi,	
	Shimizu, Each author must also sign the Copyright License Agreement	
	(CLA) before the manuscript is given finally acceptance for publication.	
	Please click	
	https://www.f6publishing.com/forms/manuscript/public/CheckCop	
	yright.aspx?msid=2E2B888FB0DC7F96&aid=242DF9691E0EEAA0, read	
	all of the contents of the CLA, and make a decision to accept and sign or	
	refuse and not to sign. Please submit the signed CLA within 5 days X Hi,	
	Takahara, Each author must also sign the Copyright License Agreement	
	(CLA) before the manuscript is given finally acceptance for publication.	
2	Please click	
2	https://www.f6publishing.com/forms/manuscript/public/CheckCop	[Y]
	yright.aspx?msid=2E2B888FB0DC7F96&aid=DAE94B3626F92467, read	
	all of the contents of the CLA, and make a decision to accept and sign or	
	refuse and not to sign. Please submit the signed CLA within 5 days X Hi,	
	Minemura, Each author must also sign the Copyright License Agreement	
	(CLA) before the manuscript is given finally acceptance for publication.	
	Please click	
	https://www.f6publishing.com/forms/manuscript/public/CheckCop	
	yright.aspx?msid=2E2B888FB0DC7F96&aid=47CC3BB3E2E556DD, read	
	all of the contents of the CLA, and make a decision to accept and sign or	
	refuse and not to sign. Please submit the signed CLA within 5 days X Hi,	
	Kashii,Each author must also sign the Copyright License Agreement	



Baishideng **Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com

(CLA) before the manuscript is given finally acceptance for publication. Please click https://www.f6publishing.com/forms/manuscript/public/CheckCop yright.aspx?msid=2E2B888FB0DC7F96&aid=FC6A3B05C36B72BE, read all of the contents of the CLA, and make a decision to accept and sign or refuse and not to sign. Please submit the signed CLA within 5 days. [Hi, Murayama, Each author must also sign the Copyright License Agreement (CLA) before the manuscript is given finally acceptance for publication. Please click https://www.f6publishing.com/forms/manuscript/public/CheckCop yright.aspx?msid=2E2B888FB0DC7F96&aid=B4658417A668A662, read all of the contents of the CLA, and make a decision to accept and sign or refuse and not to sign. Please submit the signed CLA within 5 days **I**(Hi, Murayama, Each author must also sign the Copyright License Agreement (CLA) before the manuscript is given finally acceptance for publication. Please click https://www.f6publishing.com/forms/manuscript/public/CheckCop yright.aspx?msid=2E2B888FB0DC7F96&aid=B4658417A668A662, read all of the contents of the CLA, and make a decision to accept and sign or refuse and not to sign. Please submit the signed CLA within 5 days **I**(Hi, Ito, Each author must also sign the Copyright License Agreement (CLA) before the manuscript is given finally acceptance for publication. Please click https://www.f6publishing.com/forms/manuscript/public/CheckCop vright.aspx?msid=2E2B888FB0DC7F96&aid=D25055DF52CA64C4, read



Baishideng **Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com

all of the contents of the CLA, and make a decision to accept and sign or refuse and not to sign. Please submit the signed CLA within 5 days -----2. We are very pleased to receive your revised manuscript (No. 74948). However, after our verification, we found that the language editing company mentioned in your submitted language certificate only polished the initial manuscript. Following the many changes that were introduced into the content of your manuscript during the revision process, some language problems exist in the revised manuscript. Further language polishing is required to fix all grammatical, syntactical, formatting and other related errors, in order to meet the publication requirement (Grade A). Now, you are requested to send the revised manuscript to a professional English language editing company or a native English-speaking expert to polish the language further. When you submit the subsequent polished manuscript to us, you must provide a new language certificate along with it. Once this step is completed, your manuscript will be quickly accepted and published online. Please visit the following website for the professional English language editing companies recommend: we https://www.wjgnet.com/bpg/gerinfo/240

Company Editor-in-Chief: I have reviewed the Peer-Review Report, the full text of the manuscript, and the relevant ethics documents, all of which have met the basic publishing requirements of the World Journal of Hepatology, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office's comments and the Criteria for



Baishideng **Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com

Manuscript Revision by Authors. Before final acceptance, uniform presentation should be used for figures showing the same or similar contents; for example, "Figure 1Pathological changes of atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...". Please provide the original figure documents. Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor. In order to respect and protect the author's intellectual property rights and prevent others from misappropriating figures without the author's authorization or abusing figures without indicating the source, we will indicate the author's copyright for figures originally generated by the author, and if the author has used a figure published elsewhere or that is copyrighted, the author needs to be authorized by the previous publisher or the copyright holder and/or indicate the reference source and copyrights. Please check and confirm whether the figures are original (i.e. generated de novo by the author(s) for this paper). If the picture is 'original', the author needs to add the following copyright information to the bottom right-hand side of the picture in PowerPoint (PPT): Copyright ©The Author(s) 2022. Authors are required to provide standard three-line tables, that is, only the top line, bottom line, and column line are displayed, while other table lines are hidden. The contents of each cell in the table should conform to the editing specifications, and the lines of each row or column of the table should be aligned. Do not use carriage returns or spaces to replace lines or vertical lines and do not segment cell content.



3	The fixed headings are copied.	[Y]
	The title concisely summarizes the main topic of the study and is not too	
	long (no more than 18 words). Words such as 'exploration', 'research',	
4	'analysis', 'observation', and 'investigation' are avoided. The title does	[Y]
	not start with 'The' and does not include any Arabic numbers or	
	uncommon abbreviations.	
5	A short running title is provided (no more than 6 words).	[Y]
	The authors' full family (sur)names and full/abbreviated first names are	
6	listed on the title page and are consistent with those listed in the signed	[Y]
	BPG Copyright License Agreement form.	
	The 'Author contributions' passage describes the specific contribution(s)	
	made by each author. The author's names are listed in the following	
	format: full family (sur)name followed by abbreviated first and middles	
	names.	
	e.g., "Wang CL and Liang L contributed equally to this work; Wang CL,	
7	Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research	[Y]
	study; Wang CL, Zou CC, Hong F and Wu XM performed the research;	
	Xue JZ and Lu JR contributed new reagents and analytic tools; Wang	
	CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu	
	JF wrote the manuscript. All authors have read and approve the final	
	manuscript."	
	The 'Supported by' statement describes the source(s) of financial	
8	support and includes the corresponding identification number(s) and	[N]
	program ID(s) if available, and contains no spelling errors.	
	The 'Corresponding author' passage provides the corresponding	
	author's full first and family (sur)names, abbreviated title (e.g., MD,	
9	PhD), affiliated institute's name and complete postal address (including	[Y]
	zip code) and e-mail (written in all lowercase), and contains no spelling	
	errors.	



10	The Manuscript Tracking information (<i>i.e.</i> , Received, Peer review started, First decision, Revised, Accepted, Article in press, and Published online) are provided along with the corresponding editor and	[Y]
	date for each item, and contain no spelling errors.	
11	The Abstract section is formatted according to the article-specific style (structured vs unstructured) and word count thresholds, as follows: <u>Commentary</u> , Frontier, Diagnostic Advances, Medical Ethics, <u>Minireview</u> , Review, Therapeutics Advances, and Topic Highlight: Non-structured abstract that is no less than 200 words. <u>Field of Vision</u> , Case Report and Letter to the Editor: Non-structured abstract that is no less than 150 words. <u>Research articles</u> : Structured abstract with subsections for AIM (no more than 20 words); METHODS (no less than 80 words); RESULTS (no less	[Y]
	than 120 words); and CONCLUSION (no more than 26 words).	
12	The 'Key words' list provides 5-10 keywords that reflect the main content of the study. The first letter of each keyword is capitalized, and each keyword is separated by a semicolon.	[Y]
13	The "citation" contains authors' names and manuscript title. The name of the first author should be typed in bold letters; the family (sur) name of all authors should be typed with the first letter capitalized, followed by their abbreviated first and middle initials. For example, an article by Jae Moon Yoon, Ki Young Son, Chun Sick Eom, Daniel Durrance, Sang Min Park will be written as Yoon JM, Son KY, Eom CS, Durrance D, Park SM. Pre-existing diabetes mellitus increases the risk of gastric cancer: A meta-analysis. <i>World J Gastroenterol</i> 2019; In press	[Y]
14	The 'Core tip' provides a summary (less than 100 words) of the study that outlines the most innovative and important arguments and core contents of the paper and will serve to effectively attract readers.	[Y]



	The 'INTRODUCTION' section clearly describes the relevant	
	background information for the study. Only the most relevant and	
	current (within the past 5 years) literature is cited, with the exception of	
	rare instances of seminal literature citations. All technical terms and/or	
	abbreviations are explained and/or defined, with the full name of	
15	abbreviations given upon first appearance in the text and the	[Y]
	abbreviation presented in parentheses [i.e., "computed tomography	
	(CT)"]. First-person pronouns (e.g., 'I', 'we') are used appropriately to	
	clearly indicate the work performed by the author(s). When weaknesses	
	of previous studies are described in the text to highlight the innovations	
	related to the current study, the information is presented carefully.	
	The 'MATERIALS AND METHODS' section clearly and accurately	
16	describes all materials and methods used to obtain the data presented in	[Y]
	the article and is adequate for a reader to repeat the study.	
	The 'RESULTS' section concisely describes the observational and	
	experimental results. Representative data and data that have scientific	
	significance are emphasized. Data is presented in either the text, a table	
17	or figure (i.e., chart, diagram, graph or image), but is not repeated	[Y]
	among each. Information presented in the tables and figures clearly	
	describes the trends, meaning, and inferences. Results described in	
	textual form are accurate, concise and clear.	
	Statistical symbols are accurate. Statistical significance is expressed as ${}^{a}P$	
	< 0.05, ^b P < 0.01 (P > 0.05 usually does not need to be denoted). If there	
18	are other series of <i>P</i> values, ${}^{c}P < 0.05$ and ${}^{d}P < 0.01$ are used, and a third	[Y]
	series of P values is expressed as ${}^{e}P < 0.05$ and ${}^{f}P < 0.01$. Statistical data	
	is expressed as mean \pm SD or mean \pm SE.	



19	The 'DISCUSSION' section (1) describes the main purpose and hypothesis of the study; (2) summarizes the most important results; (3) illustrates and explains the results (but does not simply repeat the data) and draws conclusions or inferences based on the results; (4) points out the limitations of the study and their impact on the results, as well as proposes further advice on future research topic(s) or direction(s); and (5) describes the theoretical significance and practical value of the findings.	[Y]
20	The 'ACKNOWLEDGEMENTS' section expresses gratitude to any individuals or organizations for technical support (<i>i.e.</i> , providing instrumentation, equipment or experimental materials, and/or assistance in experimental work), non-technical services (<i>i.e.</i> , useful inspiration, suggestions, guidance, or review), and/or any other auxiliary work.	[N]
21	The 'ARTICLE HIGHLIGHTS' section provides comments for original articles in accordance with the specified format.	[Y]
22	The 'REFERENCES' section lists the references in the Vancouver style. This style uses Arabic numeral in-text citations based on the order of the first appearance of a source in the text. For citations where the author's name is indicated in the text, a superscript number should be placed following the name (<i>i.e.</i> , "Pang <i>et al</i> "). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Ma ^[1] reported", "Pan <i>et al</i> ^[2-5] indicated"; "PCR has a high sensitivity ^[6,9] ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text (<i>e.g.</i> , Pan <i>et al</i> ^[2-5] , please see reference [8]).	[Y]



23	Journal references have been verified to ensure that there are no duplicate references and that the PMID numbers are correct. For references not yet included in PubMed: the name of Chinese journals is spelled out using Chinese Pinyin, with the first letter of each word capitalized (<i>e.g., Shijie Huaren Xiaohua Zazhi</i>); the name of journals in other languages are listed according to indexing information retrieved from Google. Book references are presented with all the information relevant to the electronic version.	[Y]
24	The number of cited references is appropriate for the article type, as follows: <u>Commentary:</u> no less than 50; <u>Review:</u> no less than 100; <u>Article:</u> no less than 30/26; <u>Case Report and Letter to the Editor:</u> no less than 1.	[Y]
25	The ethics-related statements are provided in accordance with the manuscript type (<i>e.g.</i> , Manuscript NoInstitutional review board statement, Manuscript NoAnimal care and use statement, <i>etc.</i>).	[Y]
26	The names of the peer reviewers and the scientific editor are present at the end of the paper (<i>e.g.</i> , P-Reviewer: Hugot D S-Editor: Wang JL).	[Y]
27	The order and numerical labeling of tables and figures is consistent with their appearance and presentation in the text. Symbols in tables (<i>e.g.</i> , +, -, ×, \div , *) correctly correspond to the definitions in the footnotes. Only one legend is provided for each multi-panel figure consisting of color graphs, black and white graphs, or line graphs that depicts data of the same theme. For example: Figure 1 Pathological changes in atrophic gastritis tissue before and after treatment. A:; B:; C:; D:; E:; F:	[Y]
28	Split pictures include flow charts, line graphs, histograms, and graphs including text. Unsplit pictures include meta-analysis diagrams, PCR amplification curves, and survival curves.	[Y]



Γ		
29	The author(s) highlighted the changes made to the manuscript according to the peer-reviewers' comments.	[Y]
30	The responses to the peer-reviewers' comments are consistent with the changes made to the manuscript.	[Y]
31	The revised manuscript is provided (file name: Manuscript NoReview; <i>e.g.</i> , 870- Review). The letter of peer-reviewers' comments is provided (file name: Manuscript NoPeer-review(s); <i>e.g.</i> , 870-Peer-review(s)). The response letter is provided (file name: Manuscript NoAnswering reviewers; <i>e.g.</i> , 870-Answering reviewers).	[Y]
32	The related ethics and relevant documents are provided, such as (1) Approved grant application form(s) or funding agency copy of any approval document(s) (file name: Manuscript NoGrant application form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement).	[Y]
33	All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; <i>e.g.</i> , 870-Copyright license agreement).	[Y]
34	The language certificate provided by authors who are non-native speakers of English meets the BPG requirements (file name: Manuscript NoLanguage certificate; <i>e.g.</i> , 870-Language certificate).	[Y]



35 7 36 1 2 36 1 2 36 2 36 2 36 2 36 2 36 36 2 36 36 36 36 4 37 36 36 4 36 36 4 36 4 3	The photos licensed in the Agreement for Use of Personal Photos are consistent with those in the paper (file name: Manuscript NoAgreement for use of personal photos; <i>e.g.</i> , 870-Agreement for use of personal photos). This document (Checklist of Responsibilities for Scientific Editors) has been saved under the file name: manuscript NoScientific editor work list (<i>e.g.</i> , 870-Scientific editor work list). A <i>CrossCheck</i> investigation (an effective tool for detecting unoriginal content, enabling our editors to preserve the journal's integrity and the authors' copyright) has been performed for the manuscript <i>via</i> the	[N] [Y]
36 k 1 2 2 36 2 36 2 3 36 2 4 3 36 2 4 3 36 2 4 3 36 36 1 2 4 36 36 36 36 36 36 36 36 36 36 36 36 36	been saved under the file name: manuscript NoScientific editor work list (<i>e.g.</i> , 870-Scientific editor work list). A <i>CrossCheck</i> investigation (an effective tool for detecting unoriginal content, enabling our editors to preserve the journal's integrity and the	[Y]
a v t	content, enabling our editors to preserve the journal's integrity and the	
t r f r	website: http://www.ithenticate.com/. The results document contains the following information for the manuscript: "Name of journal", "Manuscript No.", "Columns", "Title" and "Author list". The Figure of the <i>CrossCheck</i> results is saved in JPEG format (.jpg) at 1440 × 680 pixel resolution. The PDF of the <i>CrossCheck</i> results has been saved under the file name: manuscript No CrossCheck report (<i>e.g.</i> , 870-CrossCheck report). The Google searches have also been performed to further ensure publication of original content.	[Y]
38	The text of the manuscript is typed in Book Antiqua font, 12 pt, with 1.5 line spacing.	[Y]
Responsibiliteies ofFscientifica	The primary responsibilities of our scientific editors include carefully entire manuscript and all accompanying materials for: (1) errors in spellin punctuation and wording; (2) suitability of tables, figures, figure data and accurate and appropriate presentation of symbols (<i>e.g.</i> +, -, ×, \div , %, *) \div figures; and (4) complete and comprehensive revision of the manuscript	ng, grammar, d legends; (3) in tables and



	Manuscript reception and registration-Initial review by scientific editor-Peer
	$review \rightarrow End of peer review \rightarrow First round of meeting evaluation \rightarrow To be$
	accepted \rightarrow Revision by the author(s) \rightarrow Second round of meeting evaluation \rightarrow To be
	accepted/revised/rejected→Final review by the Editor-in-Chief (final quality control
Publication	for academic content and language quality) \rightarrow Final acceptance and charging of
process	$publication fee \rightarrow Language editing \rightarrow Production \rightarrow Proof reading by scientific$
	$editor {\rightarrow} Proof reading \ by \ deputy \ editor {\rightarrow} Final \ review \ by \ Editor {-} in - Chief {\rightarrow} Release \ of$
	online open-access papers in electronic form on the BPG website \rightarrow Release of online
	papers on PubMed Central \rightarrow Delivery of high-quality PDF reprints to the
	author(s) \rightarrow End of the publication process.